Talphera is currently a pre-commercial entity undergoing a high-risk strategic pivot toward the Niyad platform, characterized by a complete evaporation of revenue and persistent quarterly operating losses exceeding $3 million. The company's future viability is...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.06+4.0% vs -$0.06 | — vs — |
Q2 2026 May 13, 2026 | -$0.04+42.9% vs -$0.07 | — vs — |
Q2 2026 Mar 23, 2026 | -$0.06+20.0% vs -$0.07 | — vs $580,000 |
Q4 2025 Nov 12, 2025 | -$0.11-46.7% vs -$0.07 | $1,000 vs — |
SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C.
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced financial results for the second quarter of 2026 and provided a corporate update on the development of nafamostat.
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.
Benchmark TLPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Talphera, Inc. (TLPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.17 | $60.72M | -3.44 | — | -51035.71% | -114.16% | — | |
| $14.31 | $1.98B | -1.39 | -2.75% | -41.85% | -55.97% | — | |
| $115.13 | $13.66B | 44.97 | 37.55% | 24.86% | 180.63% | — | |
| $60.97 | $2.02B | -6.27 | -43.89% | -287.84% | -37.99% | — | |
| $24.70 | $971.57M | 154.38 | 3.63% | 1.96% | 2.13% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — |
Talphera, Inc. (TLPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Talphera, Inc. (TLPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 23, 2026·SEC
May 13, 2026·SEC
Get notified when TLPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Talphera, Inc. (TLPH) stock FAQ — growth, dividends, profitability & financials explained
Talphera, Inc. (TLPH) reported $0.0M in revenue for fiscal year 2025.
Talphera, Inc. (TLPH) reported a net loss of $15.1M for fiscal year 2025.
Talphera, Inc. (TLPH) has a return on equity (ROE) of -114.2%. Negative ROE indicates the company is unprofitable.
Talphera, Inc. (TLPH) had negative free cash flow of $12.3M in fiscal year 2025, likely due to heavy capital investments.
